Mirum Pharmaceuticals, Inc. (MIRM) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Overview
As of June 22, 2026, Mirum Pharmaceuticals, Inc. (MIRM) reported trailing twelve-month net income of -$799M, reflecting +74.6% year-over-year growth. The company earned $-13.57 per diluted share over the past four quarters, with a net profit margin of -4.5%.
Looking at the long-term picture, MIRM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$17M in fiscal 2018.
Mirum Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), RARE (-$609M net income, -85.4% margin), ACAD ($376M net income, 36.5% margin), MIRM has room to improve margins relative to the peer group. Compare MIRM vs ALNY →
MIRM Earnings vs Peers
Earnings metrics vs comparable public companies
MIRM Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$23M | +73.4% | -$22M | $-0.47 | -4.5% | -4.2% |
| 2024 | -$88M | +46.2% | -$88M | $-1.85 | -26.1% | -26.0% |
| 2023 | -$163M | -20.5% | -$109M | $-4.00 | -87.7% | -58.6% |
| 2022 | -$136M | -61.5% | -$131M | $-4.02 | -176.0% | -170.3% |
| 2021 | -$84M | +18.7% | -$173M | $-2.77 | -438.9% | -906.1% |
| 2020 | -$103M | -96.5% | -$104M | $-4.09 | - | - |
| 2019 | -$53M | -202.9% | -$55M | $-2.29 | - | - |
| 2018 | -$17M | - | -$3M | $-0.75 | - | - |
Download Data
Export MIRM earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MIRM — Frequently Asked Questions
Quick answers to the most common questions about buying MIRM stock.
What is MIRM earnings per share (EPS)?
MIRM trailing twelve-month (TTM) diluted EPS is $-13.57, reflecting +74.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Mirum Pharmaceuticals, Inc.'s net income?
Mirum Pharmaceuticals, Inc. (MIRM) trailing twelve-month net income is $-799M as of 2025. Earnings grew +74.6% year-over-year.
Is MIRM profitable?
MIRM is not currently profitable on a TTM basis, reporting a net loss of $-799M. Net margin is -4.5%. Investors should monitor for a return to profitability.
What is MIRM's earnings growth rate?
MIRM compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are MIRM's profit margins?
Mirum Pharmaceuticals, Inc. net profit margin is -4.5%, operating margin is -4.2%, and gross margin is +80.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -8.6%.
Is MIRM growing earnings?
Yes, MIRM earnings are accelerating — EPS growth of +74.6% exceeds the 5-year CAGR of N/A. TTM net income reached $-799M. Earnings momentum is strengthening.
What was MIRM's best earnings year?
Mirum Pharmaceuticals, Inc.'s highest annual net income on record is $-17M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were MIRM's earnings last quarter?
MIRM's most recent reported quarter was Q1 2026. Net income was $-790M with diluted EPS of $-13.43. For a full breakdown of all quarters, see the quarterly earnings table on this page.